PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 3):
The antibody of  claim 1 , wherein:\n (a) the CDR-H1 comprises the amino acid sequence of: (i) (SEQ\u2003ID\u2003NO:\u200315) TYAMGVS;   (ii) (SEQ\u2003ID\u2003NO:\u2003179) JYAMGVS;   (iii) (SEQ\u2003ID\u2003NO:\u2003180) TYJMGVS;   (iv) (SEQ\u2003ID\u2003NO:\u2003181) TYAJGVS;   (v) (SEQ\u2003ID\u2003NO:\u2003182) TYAMGJS;   (vi) (SEQ\u2003ID\u2003NO:\u2003183) TYAMGVJ; or\n (vii) a variant of any one of (ii) to (vi) comprising an additional J amino acid in place of a recited amino acid that is represented by a J in SEQ ID NO: 171; \n (b) the CDR-H2 comprises the amino acid sequence of: (i) (SEQ\u2003ID\u2003NO:\u200316) SIWWNGNKYNNPSLKS;   (ii) (SEQ\u2003ID\u2003NO:\u2003184) SJWWNGNKYNNPSLKS;   (iii) (SEQ\u2003ID\u2003NO:\u2003185) SIWJNGNKYNNPSLKS;   (iv) (SEQ\u2003ID\u2003NO:\u2003186) SIWWJGNKYNNPSLKS;   (v) (SEQ\u2003ID\u2003NO:\u2003187) SIWWNJNKYNNPSLKS;   (vi) (SEQ\u2003ID\u2003NO:\u2003188) SIWWNGJKYNNPSLKS;   (vii) (SEQ\u2003ID\u2003NO:\u2003189) SIWWNGNJYNNPSLKS;   (viii) (SEQ\u2003ID\u2003NO:\u2003190) SIWWNGNKJNNPSLKS;   (ix) (SEQ\u2003ID\u2003NO:\u2003191) SIWWNGNKYJNPSLKS;   (x) (SEQ\u2003ID\u2003NO:\u2003192) SIWWNGNKYNJPSLKS;   (xi) (SEQ\u2003ID\u2003NO:\u2003193) SIWWNGNKYNNJSLKS;   (xii) (SEQ\u2003ID\u2003NO:\u2003194) SIWWNGNKYNNPJLKS;   (xiii) (SEQ\u2003ID\u2003NO:\u2003195) SIWWNGNKYNNPSJKS;   (xiv) (SEQ\u2003ID\u2003NO:\u2003196) SIWWNGNKYNNPSLKJ; or\n (xv) a variant of any one of (ii) to (xiv) comprising an additional J amino acid in place of a recited amino acid that is represented by a J in SEQ ID NO: 172; \n (c) the CDR-H3 comprises the amino acid sequence of: (i) (SEQ\u2003ID\u2003NO:\u200317) SRIIRFTDYVMDA; (ii) (SEQ\u2003ID\u2003NO:\u2003197) JRIIRFTDYVMDA; (iii) (SEQ\u2003ID\u2003NO:\u2003198) SJIIRFTDYVMDA; (iv) (SEQ\u2003ID\u2003NO:\u2003199) SRIJRFTDYVMDA; (v) (SEQ\u2003ID\u2003NO:\u2003200) SRIIJFTDYVMDA; (vi) (SEQ\u2003ID\u2003NO:\u2003201) SRIIRJTDYVMDA; (vii) (SEQ\u2003ID\u2003NO:\u2003202) SRIIRFTDYVJDA; (viii) (SEQ\u2003ID\u2003NO:\u2003203) SRIIRFTDYVMJA; (ix) (SEQ\u2003ID\u2003NO:\u2003204) SRIIRFTDYVMDJ; or\n (x) a variant of any one of (ii) to (ix) comprising an additional J amino acid in place of a recited amino acid that is represented by a J in SEQ ID NO: 173; \n (d) the CDR-L1 comprises the amino acid sequence of: (i) (SEQ\u2003ID\u2003NO:\u200318) RASEDIYNDLA;   (ii) (SEQ\u2003ID\u2003NO:\u2003205) JASEDIYNDLA;   (iii) (SEQ\u2003ID\u2003NO:\u2003206) RJSEDIYNDLA;   (iv) (SEQ\u2003ID\u2003NO:\u2003207) RAJEDIYNDLA;   (v) (SEQ\u2003ID\u2003NO:\u2003208) RASJDIYNDLA;   (vi) (SEQ\u2003ID\u2003NO:\u2003209) RASEJIYNDLA;   (vii) (SEQ\u2003ID\u2003NO:\u2003210) RASEDJYNDLA;   (viii) (SEQ\u2003ID\u2003NO:\u2003211) RASEDIJNDLA;   (ix) (SEQ\u2003ID\u2003NO:\u2003212) RASEDIYJDLA;   (x) (SEQ\u2003ID\u2003NO:\u2003213) RASEDIYNDLJ; or\n (xi) a variant of any one of (ii) to (x) comprising an additional J amino acid in place of a recited amino acid that is represented by a J in SEQ ID NO: 174; \n (e) the CDR-L2 comprises the amino acid sequence of: (i) (SEQ\u2003ID\u2003NO:\u200319) NANSLHT;   (ii) (SEQ\u2003ID\u2003NO:\u2003214) JANSLHT;   (iii) (SEQ\u2003ID\u2003NO:\u2003215) NJNSLHT;   (iv) (SEQ\u2003ID\u2003NO:\u2003216) NAJSLHT;   (v) (SEQ\u2003ID\u2003NO:\u2003217) NANJLHT;   (vi) (SEQ\u2003ID\u2003NO:\u2003218) NANSJHT;   (vii) (SEQ\u2003ID\u2003NO:\u2003219) NANSLJT;   (viii) (SEQ\u2003ID\u2003NO:\u2003220) NANSLHJ; or\n (ix) a variant of any one of (ii) to (viii) comprising an additional J amino acid in place of a recited amino acid that is represented by a J in SEQ ID NO: 175; and/or \n (f) the CDR-L3 comprises the amino acid sequence of: (i) (SEQ\u2003ID\u2003NO:\u200320) QQYYDYPLT;   (ii) (SEQ\u2003ID\u2003NO:\u2003221) JQYYDYPLT;   (iii) (SEQ\u2003ID\u2003NO:\u2003222) QJYYDYPLT;   (iv) (SEQ\u2003ID\u2003NO:\u2003223) QQJYDYPLT;   (v) (SEQ\u2003ID\u2003NO:\u2003224) QQYYDYPLJ; or\n (vi) a variant of any one of (ii) to (v) comprising an additional J amino acid in place of a recited amino acid that is represented by a J in SEQ ID NO: 176.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7429632627193788
- 35 USC 102 Novelty (BERT): 0.5353261657860731
- Combined Prediction Score: 0.7221995530260483
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 260.6000673146367

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test